| Literature DB >> 33190590 |
Xiao-Tan Zhang1,2, Guang Wang1, Liu-Fang Ye1, Yu Pu1, Run-Tong Li1, Jianxin Liang1, Lijun Wang3, Kenneth Ka Ho Lee4, Xuesong Yang1,5.
Abstract
Baicalin is a flavone glycoside that possesses numerous pharmacological properties. but its protective mode of action in kidney injury induced by diabetes mellitus remains incompletely understood. Using a streptozotocin (STZ)-induced diabetic mouse model, we found that baicalin could ameliorate diabetes-induced the pathological changes of the kidney function and morphology through suppressing inflammation and oxidative stress. Furthermore, baicalin treatment could alleviate interstitial fibrosis in the diabetic kidney via inhibiting epithelial-to-mesenchymal transition (EMT), which was accompanied by a sharp upregulation of Klotho, the endogenous inhibitor of renal fibrosis. We further verified that baicalin-rescued expression of Klotho was associated with Klotho promoter hypomethylation due to aberrant methyltransferase 3a expressions. Klotho knockdown via RNA interferences largely abrogated the anti-renal fibrotic effects of Baicalin in HK2 cells. These findings suggested that baicalin could alleviate renal injury-induced by diabates through partly modulating Klotho promoter methylation, which provides new insights into the treatment of diabetic nephropathy.Entities:
Keywords: DNA methylation; Diabetes; Klotho; fibrosis; kidney
Year: 2020 PMID: 33190590 PMCID: PMC7751632 DOI: 10.1080/15384101.2020.1843815
Source DB: PubMed Journal: Cell Cycle ISSN: 1551-4005 Impact factor: 4.534